MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.
|Videos|March 15, 2011
Dr. Langmuir Discusses Vandetanib Clinical Trials
Author(s)Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5